Performance
Stock factor profile
AJANTA PHARM
AJANTPHARM · Healthcare · Pharmaceuticals & Biotechnology
Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 7,713 full-time employees. The company went IPO on 2000-06-05. The firm provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The firm is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. The company has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The firm's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
Equity review factors
Factor profile
Factor scores are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags and screen results for AJANTA PHARM are part of the Wright portfolio review.
Run your free portfolio reviewFundamental snapshot
Fundamentals at a glance
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.